2018 Essential Hypertension Drug Development Pipeline Analysis Report- Companies, Drugs, Clinical Trials, Latest Developments in Essential Hypertension Market
2018 Essential Hypertension Drug Development Pipeline Analysis Report- Companies, Drugs, Clinical Trials, Latest Developments in Essential Hypertension Market is a comprehensive report on Essential Hypertension market.
To assist researchers, investors and business development managers, VPA Research has come up with a comprehensive report on Essential Hypertension pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.
Current status, developmental phase, participating companies and entities, recent developments, orphan drug/ fast track/ other designations, drug class are provided for each Essential Hypertension pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.
In addition to complete details of each product, the report provides key trends in Essential Hypertension pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.
To assist researchers, investors and business development managers, VPA Research has come up with a comprehensive report on Essential Hypertension pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.
Current status, developmental phase, participating companies and entities, recent developments, orphan drug/ fast track/ other designations, drug class are provided for each Essential Hypertension pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.
In addition to complete details of each product, the report provides key trends in Essential Hypertension pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.
1 TABLE OF CONTENTS
1.1 List of LIST OF FIGURES
1.2 List of Tables
2 ESSENTIAL HYPERTENSION PIPELINE ANALYSIS
2.1 Disease and Pipeline Overview
2.2 Essential Hypertension Pipeline Snapshot
2.3 Essential Hypertension Pipeline by Phase
2.4 Essential Hypertension Pipeline by Company
2.5 Essential Hypertension Pipeline by Mechanism of Action
3 ESSENTIAL HYPERTENSION- COMPANY WISE PIPELINE ANALYSIS
Actelion Ltd
Bayer AG
Beijing CoSci Med-Tech Co.,Ltd
Boryung Pharmaceutical Co., Ltd
Chong Kun Dang Pharmaceutical Corp.
Daiichi Sankyo Company, Limited
HanAll Biopharma Co., Ltd.
Hypogen, Inc.
Il Dong Pharmaceutical Co Ltd
Merck KGaA
Novartis International AG
Quantum Genomics SA
RMJ Holdings, LLC
Shin Poong Pharmaceutical Co Ltd
Takeda Pharmaceutical Company Limited
Theracos, Inc.
Yuhan Co, Ltd.
4 ESSENTIAL HYPERTENSION R&D PIPELINE SNAPSHOTS
Drug wise Pipeline Details
Therapeutic Candidate Name
Originator
Co-Developer/ License Partner
Orphan Drug Designation
Development Phase
Mechanism of Action
Current Status
Ongoing Clinical Trial Details
5 RECENT DEVELOPMENTS IN ESSENTIAL HYPERTENSION PIPELINE
6 APPENDIX
6.1 About VPA Research
6.2 Sources and Research Methodology
1.1 List of LIST OF FIGURES
1.2 List of Tables
2 ESSENTIAL HYPERTENSION PIPELINE ANALYSIS
2.1 Disease and Pipeline Overview
2.2 Essential Hypertension Pipeline Snapshot
2.3 Essential Hypertension Pipeline by Phase
2.4 Essential Hypertension Pipeline by Company
2.5 Essential Hypertension Pipeline by Mechanism of Action
3 ESSENTIAL HYPERTENSION- COMPANY WISE PIPELINE ANALYSIS
Actelion Ltd
Bayer AG
Beijing CoSci Med-Tech Co.,Ltd
Boryung Pharmaceutical Co., Ltd
Chong Kun Dang Pharmaceutical Corp.
Daiichi Sankyo Company, Limited
HanAll Biopharma Co., Ltd.
Hypogen, Inc.
Il Dong Pharmaceutical Co Ltd
Merck KGaA
Novartis International AG
Quantum Genomics SA
RMJ Holdings, LLC
Shin Poong Pharmaceutical Co Ltd
Takeda Pharmaceutical Company Limited
Theracos, Inc.
Yuhan Co, Ltd.
4 ESSENTIAL HYPERTENSION R&D PIPELINE SNAPSHOTS
Drug wise Pipeline Details
Therapeutic Candidate Name
Originator
Co-Developer/ License Partner
Orphan Drug Designation
Development Phase
Mechanism of Action
Current Status
Ongoing Clinical Trial Details
5 RECENT DEVELOPMENTS IN ESSENTIAL HYPERTENSION PIPELINE
6 APPENDIX
6.1 About VPA Research
6.2 Sources and Research Methodology
LIST OF FIGURES
Figure 1: Essential Hypertension Pipeline by Phase, H2- 2018
Figure 2: Essential Hypertension Pipeline by Companies, H2- 2018
Figure 3: Company Wise Pipeline Drug Phases, H2- 2018
Figure 4: Essential Hypertension Pipeline by Mechanism of Action, H2- 2018
Figure 5: Mechanism Wise Pipeline Drug Phases, H2- 2018
Figure 1: Essential Hypertension Pipeline by Phase, H2- 2018
Figure 2: Essential Hypertension Pipeline by Companies, H2- 2018
Figure 3: Company Wise Pipeline Drug Phases, H2- 2018
Figure 4: Essential Hypertension Pipeline by Mechanism of Action, H2- 2018
Figure 5: Mechanism Wise Pipeline Drug Phases, H2- 2018
LIST OF TABLES
Essential Hypertension Pipeline by Phase, H2- 2018
Essential Hypertension Pipeline by Companies, H2- 2018
Essential Hypertension Pipeline by Mechanism of Action, H2- 2018
Table 1: Actelion Ltd Essential Hypertension Pipeline Drugs, H2- 2018
Table 2: Bayer AG Essential Hypertension Pipeline Drugs, H2- 2018
Table 3: Beijing CoSci Med-Tech Co.,Ltd Essential Hypertension Pipeline Drugs, H2- 2018
Table 4: Boryung Pharmaceutical Co., Ltd Essential Hypertension Pipeline Drugs, H2- 2018
Table 5: Chong Kun Dang Pharmaceutical Corp. Essential Hypertension Pipeline Drugs, H2- 2018
Table 6: Daiichi Sankyo Company, Limited Essential Hypertension Pipeline Drugs, H2- 2018
Table 7: HanAll Biopharma Co., Ltd. Essential Hypertension Pipeline Drugs, H2- 2018
Table 8: Hypogen, Inc. Essential Hypertension Pipeline Drugs, H2- 2018
Table 9: Il Dong Pharmaceutical Co Ltd Essential Hypertension Pipeline Drugs, H2- 2018
Table 10: Merck KGaA Essential Hypertension Pipeline Drugs, H2- 2018
Table 11: Novartis International AG Essential Hypertension Pipeline Drugs, H2- 2018
Table 12: Quantum Genomics SA Essential Hypertension Pipeline Drugs, H2- 2018
Table 13: RMJ Holdings, LLC Essential Hypertension Pipeline Drugs, H2- 2018
Table 14: Shin Poong Pharmaceutical Co Ltd Essential Hypertension Pipeline Drugs, H2- 2018
Table 15: Takeda Pharmaceutical Company Limited Essential Hypertension Pipeline Drugs, H2- 2018
Table 16: Theracos, Inc. Essential Hypertension Pipeline Drugs, H2- 2018
Table 17: Yuhan Co, Ltd. Essential Hypertension Pipeline Drugs, H2- 2018
Essential Hypertension Pipeline by Phase, H2- 2018
Essential Hypertension Pipeline by Companies, H2- 2018
Essential Hypertension Pipeline by Mechanism of Action, H2- 2018
Table 1: Actelion Ltd Essential Hypertension Pipeline Drugs, H2- 2018
Table 2: Bayer AG Essential Hypertension Pipeline Drugs, H2- 2018
Table 3: Beijing CoSci Med-Tech Co.,Ltd Essential Hypertension Pipeline Drugs, H2- 2018
Table 4: Boryung Pharmaceutical Co., Ltd Essential Hypertension Pipeline Drugs, H2- 2018
Table 5: Chong Kun Dang Pharmaceutical Corp. Essential Hypertension Pipeline Drugs, H2- 2018
Table 6: Daiichi Sankyo Company, Limited Essential Hypertension Pipeline Drugs, H2- 2018
Table 7: HanAll Biopharma Co., Ltd. Essential Hypertension Pipeline Drugs, H2- 2018
Table 8: Hypogen, Inc. Essential Hypertension Pipeline Drugs, H2- 2018
Table 9: Il Dong Pharmaceutical Co Ltd Essential Hypertension Pipeline Drugs, H2- 2018
Table 10: Merck KGaA Essential Hypertension Pipeline Drugs, H2- 2018
Table 11: Novartis International AG Essential Hypertension Pipeline Drugs, H2- 2018
Table 12: Quantum Genomics SA Essential Hypertension Pipeline Drugs, H2- 2018
Table 13: RMJ Holdings, LLC Essential Hypertension Pipeline Drugs, H2- 2018
Table 14: Shin Poong Pharmaceutical Co Ltd Essential Hypertension Pipeline Drugs, H2- 2018
Table 15: Takeda Pharmaceutical Company Limited Essential Hypertension Pipeline Drugs, H2- 2018
Table 16: Theracos, Inc. Essential Hypertension Pipeline Drugs, H2- 2018
Table 17: Yuhan Co, Ltd. Essential Hypertension Pipeline Drugs, H2- 2018
